As of March 18, 2026, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

Here's the latest list of major overbought players in this sector.

Arcellx Inc (NASDAQ:ACLX)

  • On Feb. 23, Gilead Sciences Inc. (NASDAQ:GILD) announced it is acquiring Arcellx to enhance its long-term oncology prospects. "This agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. The company's stock gained around 66% over the past month and has a 52-week high of $114.80.
  • RSI Value: 83.4                                
  • ACLX Price Action: Shares of Arcellx gained 0.1% to close at $114.52 on Tuesday.
  • Edge Stock Ratings: 91.13 Momentum score.

Atea Pharmaceuticals Inc (NASDAQ:AVIR)

  • On March 9, Evercore ISI Group analyst Jonathan Miller maintained Atea Pharmaceuticals with an Outperform rating and raised the price target from $6 to $10. The company's stock gained around 33% over the past month and has a 52-week high of $6.45.
  • RSI Value: 82.1
  • AVIR Price Action: Shares of Atea Pharmaceuticals rose 1.3% to close at $6.13 on Tuesday.

Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock